Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice

被引:22
|
作者
Scalcon, Valeria [1 ]
Folda, Alessandra [1 ]
Lupo, Maria Giovanna [2 ]
Tonolo, Federica [1 ]
Pei, Naixuan [3 ]
Battisti, Ilaria [1 ,4 ,6 ]
Ferri, Nicola [2 ]
Arrigoni, Giorgio [1 ,4 ,6 ]
Bindoli, Alberto [5 ]
Holmgren, Arne [3 ]
Coppo, Lucia [3 ]
Rigobello, Maria Pia [1 ]
机构
[1] Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy
[2] Univ Padua, Dept Med, I-35121 Padua, Italy
[3] Karolinska Inst, Dept Med Biochem & Biophys, SE-17165 Stockholm, Sweden
[4] Univ Padua, Prote Ctr, I-35129 Padua, Italy
[5] Univ Padua, Inst Neurosci, CNR, Dept Biomed Sci, I-35131 Padua, Italy
[6] Azienda Osped Padova, I-35129 Padua, Italy
来源
REDOX BIOLOGY | 2022年 / 51卷
基金
瑞典研究理事会;
关键词
Glutaredoxin; 2; Mitochondria; Lipid metabolism; ROS production; MAFLD; Mouse model; CHOLESTEROL-METABOLISM; EXPRESSION PATTERN; OXIDATIVE STRESS; GLUTATHIONE; THIOLTRANSFERASE; IDENTIFICATION; THIOREDOXIN; DYSREGULATION; APOPTOSIS; PROTEINS;
D O I
10.1016/j.redox.2022.102277
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glutaredoxin 2 (Grx2) is a glutathione-dependent oxidoreductase that facilitates glutathionylation/deglutathionylation of target proteins. The main variants of Grx2 are the mitochondrial Grx2a and the cytosolic Grx2c. The aim of this study was to investigate the specific role of mitochondrial Grx2 in vivo using a mitochondrial Grx2 depleted (mGD) mouse model. mGD mice displayed an altered mitochondrial morphology and functioning. Furthermore, the lack of Grx2 in the mitochondrial compartment is responsible for increased blood lipid levels under a normal diet, a metabolic dysfunction-associated fatty liver disease (MAFLD) phenotype and a decreased glycogen storage capacity. In addition, depleting Grx2a leads to an alteration in abundance and in glutathionylation pattern of different mitochondrial enzymes, highlighting the selective role of Grx2 in the regulation of metabolic pathways. Overall, our findings identify the involvement of mitochondrial Grx2a in the regulation of cell metabolism and highlight a previously unknown association between Grx2 and MAFLD.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [2] A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
    Hammoutene, Adel
    Laouirem, Samira
    Albuquerque, Miguel
    Colnot, Nathalie
    Brzustowski, Angelique
    Valla, Dominique
    Provost, Nicolas
    Delerive, Philippe
    Paradis, Valerie
    JHEP REPORTS, 2023, 5 (10)
  • [3] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260
  • [4] Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
    Zhao, Ying
    Zhou, Yanni
    Wang, Dan
    Huang, Ziwei
    Xiao, Xiong
    Zheng, Qing
    Li, Shengfu
    Long, Dan
    Feng, Li
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (24)
  • [5] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [6] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [7] Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
    Barchetta, Ilaria
    Cimini, Flavia Agata
    Cavallo, Maria Gisella
    NUTRIENTS, 2020, 12 (11) : 1 - 14
  • [8] Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications
    Hu, Shuwei
    Ai, Yingjie
    Hu, Chencheng
    Bawa, Fathima N. Cassim
    Xu, Yanyong
    GENES & DISEASES, 2025, 12 (03)
  • [9] Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
    Zhou, Xiao-Dong
    Cai, Jingjing
    Targher, Giovanni
    Byrne, Christopher D.
    Shapiro, Michael D.
    Sung, Ki-Chul
    Somers, Virend K.
    Chahal, C. Anwar A.
    George, Jacob
    Chen, Li-Li
    Zhou, Yong
    Zheng, Ming-Hua
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [10] Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models
    Zhao, Qiong-Ya
    Ge, Ling-Hong
    Zhang, Kun
    Chen, Hai-Feng
    Zhan, Xin-Xin
    Yang, Yue
    Dang, Qing-Lin
    Zheng, Yi
    Zhou, Huai-Bin
    Lyu, Jian-Xin
    Fang, He-Zhi
    ZOOLOGICAL RESEARCH, 2020, 41 (05) : 539 - 551